Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
UK accepts J&J's money-back guarantee
It's official: the UK's National Health Service will start using Johnson & Johnson's Velcade, under an unprecedented money-back-guarantee program. Patients who respond to the drug will be fully funded. Patients who respond only minimally or not all all will be taken off Velcade, and J&J will refund the cost to NHS. The guarantee was the only way J&J could persuade the National Institute for Clinical Excellence--the drug gatekeepers for NHS--to reimburse for the drug at all.
- check out the CNN Money report
- read an analysis of the deal in The Telegraph
Related Articles:
J&J drug gets money-back guarantee. Report
Positive Velcade data fuels stock rise. Report
NHS fights expensive Alzheimer's drugs. Report
Metric: Biotech drugs fueling costs. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
